Does statin therapy improve short-term clinical outcomes in acute coronary syndromes?
Paul Durrington
Correspondence Cardiovascular Research Group, Division of Cardiovascular and Endocrine Sciences, Core Technology Facility (3rd Floor), University of Manchester, 46 Grafton Street, Manchester M13 9NT, UK
Email pdurrington@manchester.ac.uk
This article has no abstract so we have provided the first paragraph of the full text.
Statins undoubtedly diminish the risk of coronary heart disease (CHD) and stroke, both in primary and secondary prevention. For every 1 mmol/l (39 mg/dl) decrease in LDL cholesterol, this therapy is associated with an approximately 21% decrease in the risk of cardiovascular disease (combined CHD and stroke) compared with controls (either placebo or usual care).1 How rapidly this benefit occurs and whether early statin treatment offers an immediate advantage in the management of ACS are two questions that have attracted considerable attention.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
